Global Cord Blood (NYSE:CO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Global Cord Blood (NYSE:COFree Report) in a research report released on Sunday morning. The brokerage issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Price Performance

Shares of Global Cord Blood stock opened at $1.75 on Friday. The firm has a market cap of $212.71 million, a price-to-earnings ratio of 2.73 and a beta of 0.16. The stock’s 50-day moving average is $1.33 and its 200 day moving average is $1.38. Global Cord Blood has a one year low of $2.03 and a one year high of $5.50.

Global Cord Blood Company Profile

(Get Free Report)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Read More

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.